The dominance of the US, and its technology companies in particular, has become an accepted feature of global stock markets.

Popular diabetes drugs such as Ozempic and Trulicity are among 25 drugs Medicare has spent the most on but hasn't yet ...

Stada has lined up a new independent chairman and board of directors in a key step for the private equity-backed German drug ...

Valo Health is eligible for a further $1.9 billion in potential milestone payments for up to nine new drug programs "Novo Nordisk, Valo Health Expand Drug Discovery and Development Pact -- Update," at ...

J.P. Morgan releases its annual look-ahead days before the entire biopharma industry descends on San Francisco for the annual ...

Novo Nordisk on Wednesday announced an expanded deal with healthtech firm Valo Health to use AI to fuel drug discovery.

A Danish team thinks it can aid rAAV manufacturers, who may not be able to spend three to five years working on a project ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs for obesity and diabetes.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Poor nutrition during pregnancy can have serious consequences for both maternal and child health. A new research collaboration – 'Mother's Micronutrient Supplement for Pregnancy and Lactation' (MoMS) ...

Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock ...